ISACSON CHRISTINA K. 4
4 · Magenta Therapeutics, Inc. · Filed Jun 27, 2018
Insider Transaction Report
Form 4
ISACSON CHRISTINA K.
Chief Business Officer
Transactions
- Conversion
Common Stock
2018-06-25+2,912→ 103,531 total - Conversion
Series A Preferred Stock
2018-06-25−6,670→ 0 total→ Common Stock (2,581 underlying) - Conversion
Series B Preferred Stock
2018-06-25−857→ 0 total→ Common Stock (331 underlying)
Footnotes (1)
- [F1]The Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date.